Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorWomen's Hospital School Of Medicine Zhejiang University
About this trial
Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.
Eligibility criteria
Qualifiers
Age:18 years or older.
Histologically confirmed endometrial cancer (excluding carcinosarcoma).
FIGO (2009) stage I to IIIC2 disease that is considered surgically completely resectable.
Must agree to use contraception from the time of informed consent until at least 5 months after the last dose of the investigational product.
Disqualifiers
Myocardial infarction;
Unstable angina pectoris;
Congestive heart failure of New York Heart Association (NYHA) Class III or IV
Poorly controlled hypertension despite appropriate treatment (e.g., sustained systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg for ≥ 24 hours)
Trial design
Treatments tested in this trial
- Iparomlimab and Tuvonralimab (QL1706)
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov